PharmiOnyx
If you’ve ever been curious about how today’s breakthrough therapies are made, this conversation is for you. The landscape of modern medicine is shifting toward increasingly complex biotherapeutic modalities, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and gene/cell therapies etc. Ensuring the success of these programs requires a mastery of Chemistry, Manufacturing, and Controls (CMC), a framework that guarantees the safety, identity, and potency of each batch produced. This journey involves intricate upstream cell culture and downstream purification processes, all governed by rigorous Quality by Design (QbD) principles and advanced analytical characterization. Navigating the path from discovery to regulatory approval (BLA) demands a deep understanding of the Common Technical Document (CTD) and the evolving global guidelines for these complex medicines. Want to explore the technical blueprints and regulatory strategies behind these life-saving treatments? Listen to my latest podcast, where we dive into the drug development journey for different biologic modalities and the critical steps needed to get them to the patients who need them most!
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der PharmiOnyx-Community!